Literature DB >> 29728788

Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice.

Vishal Jindal1, Ena Arora2, Muhammad Masab3, Sorab Gupta4.   

Abstract

Chimeric antigen receptor (CAR) T cell therapy is genetically engineered tumor antigen-specific anticancer immunotherapy, which after showing great success in hematological malignancies is currently being tried in advanced solid tumors like pancreatic cancer. Immunosuppressive tumor microenvironment and dense fibrous stroma are some of the limitation in the success of this novel therapy. However, genetic modifications and combination therapy is the topic of the research to improve its efficacy. In this article, we summarize the current state of knowledge, limitations, and future prospects for CAR T cell therapy in pancreatic cancer.

Entities:  

Keywords:  CAR T cell therapy; Immunotherapy; Pancreatic ductal adenocarcinoma; Tumor microenvironment

Mesh：

Substances：

Year:  2018        PMID： 29728788     DOI： 10.1007/s12032-018-1145-0

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  84 in total

Review 1.  Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions.

Authors:  Chien-Chung Chang; Michael Campoli; Soldano Ferrone
Journal:  Adv Cancer Res       Date:  2005       Impact factor: 6.242

2.  Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

Authors:  Dung T Le; Andrea Wang-Gillam; Vincent Picozzi; Tim F Greten; Todd Crocenzi; Gregory Springett; Michael Morse; Herbert Zeh; Deirdre Cohen; Robert L Fine; Beth Onners; Jennifer N Uram; Daniel A Laheru; Eric R Lutz; Sara Solt; Aimee Luck Murphy; Justin Skoble; Ed Lemmens; John Grous; Thomas Dubensky; Dirk G Brockstedt; Elizabeth M Jaffee
Journal:  J Clin Oncol       Date:  2015-01-12       Impact factor: 44.544

Review 3.  The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues.

Authors:  S Hammarström
Journal:  Semin Cancer Biol       Date:  1999-04       Impact factor: 15.707

4.  Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma.

Authors:  H Safran; M Steinhoff; S Mangray; R Rathore; T C King; L Chai; K Berzein; T Moore; D Iannitti; P Reiss; T Pasquariello; P Akerman; D Quirk; R Mass; L Goldstein; U Tantravahi
Journal:  Am J Clin Oncol       Date:  2001-10       Impact factor: 2.339

5.  T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice.

Authors:  Markus Chmielewski; Olga Hahn; Gunter Rappl; Michael Nowak; Ingo H Schmidt-Wolf; Andreas A Hombach; Hinrich Abken
Journal:  Gastroenterology       Date:  2012-06-27       Impact factor: 22.682

6.  Identification of pancreatic cancer stem cells.

Authors:  Chenwei Li; David G Heidt; Piero Dalerba; Charles F Burant; Lanjing Zhang; Volkan Adsay; Max Wicha; Michael F Clarke; Diane M Simeone
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

7.  Current concepts in the diagnosis and management of cytokine release syndrome.

Authors:  Daniel W Lee; Rebecca Gardner; David L Porter; Chrystal U Louis; Nabil Ahmed; Michael Jensen; Stephan A Grupp; Crystal L Mackall
Journal:  Blood       Date:  2014-05-29       Impact factor: 22.113

8.  Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer.

Authors:  Stephanie K Bunt; Ashley M Mohr; Jennifer M Bailey; Paul M Grandgenett; Michael A Hollingsworth
Journal:  Cancer Immunol Immunother       Date:  2012-08-05       Impact factor: 6.968

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  Pancreatic tumors and immature immunosuppressive myeloid cells in blood and spleen: role of inhibitory co-stimulatory molecules PDL1 and CTLA4. An in vivo and in vitro study.

Authors:  Daniela Basso; Paola Fogar; Massimo Falconi; Elisa Fadi; Cosimo Sperti; Chiara Frasson; Eliana Greco; Domenico Tamburrino; Sara Teolato; Stefania Moz; Dania Bozzato; Michela Pelloso; Andrea Padoan; Giuseppe De Franchis; Elisa Gnatta; Monica Facco; Carlo-Federico Zambon; Filippo Navaglia; Claudio Pasquali; Giuseppe Basso; Gianpietro Semenzato; Sergio Pedrazzoli; Paolo Pederzoli; Mario Plebani
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240
View more
  4 in total

Review 1.  Dilemma and Challenge of Immunotherapy for Pancreatic Cancer.

Authors:  Jia Wu; Jianting Cai
Journal:  Dig Dis Sci       Date:  2020-03-05       Impact factor: 3.199

Review 2.  Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer.

Authors:  Daniel Sur; Andrei Havasi; Calin Cainap; Gabriel Samasca; Claudia Burz; Ovidiu Balacescu; Iulia Lupan; Diana Deleanu
Journal:  J Clin Med       Date:  2020-01-09       Impact factor: 4.241

Review 3.  Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.

Authors:  Jia-Qiao Fan; Meng-Fei Wang; Hai-Long Chen; Dong Shang; Jugal K Das; Jianxun Song
Journal:  Mol Cancer       Date:  2020-02-15       Impact factor: 27.401

Review 4.  Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis.

Authors:  Wenting Zhang; Qinghua Huang; Weiwei Xiao; Yue Zhao; Jiang Pi; Huan Xu; Hongxia Zhao; Junfa Xu; Colin E Evans; Hua Jin
Journal:  Front Immunol       Date:  2020-01-28       Impact factor: 7.561
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.